XNAS · Healthcare · Biotechnology
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.73 | -1.71 | -134.25% | $4.5M | ❌ Miss | -2.00% | -4.84% | — |
| 2026-02-25 | Q4 2025 | -0.61 | -0.09 | +85.25% | $28.2M | ✅ Beat | -0.25% | +6.34% | -4.67% |
| 2025-11-05 |
| Q3 2025 |
| -0.71 |
| -0.08 |
| +88.73% |
| $21.0M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.74 | -0.41 | +44.59% | $43.6M | ✅ Beat | +4.14% | +3.07% | +14.15% |
| 2025-05-07 | Q1 2025 | -0.57 | -0.66 | -15.79% | $32.7M | ❌ Miss | +10.08% | +1.94% | +20.85% |
| 2025-02-27 | Q4 2024 | -0.79 | -0.62 | +21.52% | $52.8M | ✅ Beat | — | — | — |
| 2024-11-06 | Q3 2024 | -0.96 | -0.71 | +26.04% | $10.7M | ✅ Beat | — | — | — |
| 2024-08-05 | Q2 2024 | -0.88 | -1.07 | -21.59% | $17.0M | ❌ Miss | +0.39% | -11.14% | -6.47% |
Showing last 8 quarters.